Banque Pictet & Cie SA decreased its stake in shares of Stryker Corporation (NYSE:SYK) by 53.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,350 shares of the medical technology company’s stock after selling 6,200 shares during the period. Banque Pictet & Cie SA’s holdings in Stryker were worth $760,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Stryker by 2.8% in the second quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock valued at $3,341,643,000 after purchasing an additional 657,656 shares during the period. BlackRock Inc. grew its position in shares of Stryker by 5.2% in the second quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock valued at $3,208,017,000 after purchasing an additional 1,139,082 shares during the period. Geode Capital Management LLC grew its position in shares of Stryker by 6.3% in the first quarter. Geode Capital Management LLC now owns 2,786,406 shares of the medical technology company’s stock valued at $366,255,000 after purchasing an additional 166,133 shares during the period. Jensen Investment Management Inc. grew its position in shares of Stryker by 11.3% in the third quarter. Jensen Investment Management Inc. now owns 2,472,476 shares of the medical technology company’s stock valued at $351,141,000 after purchasing an additional 251,685 shares during the period. Finally, Morgan Stanley grew its position in shares of Stryker by 17.9% in the first quarter. Morgan Stanley now owns 2,144,472 shares of the medical technology company’s stock valued at $282,320,000 after purchasing an additional 325,661 shares during the period. 74.97% of the stock is owned by institutional investors.
Shares of Stryker Corporation (SYK) traded down $3.51 on Monday, hitting $152.36. The company’s stock had a trading volume of 1,351,039 shares, compared to its average volume of 1,182,374. The firm has a market capitalization of $57,020.00, a PE ratio of 24.70, a PEG ratio of 2.45 and a beta of 0.78. Stryker Corporation has a 12 month low of $111.22 and a 12 month high of $160.62. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.39 earnings per share. analysts predict that Stryker Corporation will post 6.47 EPS for the current year.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the transaction, the insider now owns 83,207 shares in the company, valued at $12,925,375.38. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 7.40% of the company’s stock.
SYK has been the subject of a number of recent analyst reports. BidaskClub raised Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Zacks Investment Research downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Oppenheimer reaffirmed a “hold” rating on shares of Stryker in a research report on Wednesday, August 23rd. Canaccord Genuity reiterated a “buy” rating and issued a $155.00 target price (down previously from $158.00) on shares of Stryker in a report on Thursday, August 24th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $148.00 target price on shares of Stryker in a report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $152.10.
WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/stryker-corporation-syk-shares-sold-by-banque-pictet-cie-sa.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.